Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2022-02-11
3:12 pm
Sale
13GAclaris Therapeutics, Inc.
ACRS
Foresite Capital Fund III L.P.4,657,277
7.6%
-1,954,904decrease
(-29.57%)
View
2021-02-16
10:41 am
Sale
13GCymaBay Therapeutics, Inc.
CBAY
Foresite Capital Fund III L.P.3,428,898
5%
-390,828decrease
(-10.23%)
View
2021-02-11
2:56 pm
Purchase
13GAclaris Therapeutics, Inc.
ACRS
Foresite Capital Fund III L.P.6,612,181
13.7%
4,381,241increase
(+196.39%)
View
2020-10-26
7:47 pm
Purchase
13GAclaris Therapeutics, Inc.
ACRS
Foresite Capital Fund III L.P.2,230,940
5.2%
2,230,940increase
(New Position)
View
2020-02-13
9:17 pm
Sale
13GCymaBay Therapeutics, Inc.
CBAY
Foresite Capital Fund III L.P.3,819,726
5.6%
-398,633decrease
(-9.45%)
View
2020-02-13
9:16 pm
Sale
13GReplimune Group, Inc.
REPL
Foresite Capital Fund III L.P.313,922
0.8%
-1,695,390decrease
(-84.38%)
View
2019-02-13
1:00 pm
Purchase
13GAchaogen Inc.
AKAO
Foresite Capital Fund III L.P.2,864,664
6.2%
489,664increase
(+20.62%)
View
2019-02-13
1:00 pm
Purchase
13GCymaBay Therapeutics, Inc.
CBAY
Foresite Capital Fund III L.P.4,218,359
7.1%
1,363,857increase
(+47.78%)
View
2019-02-13
1:00 pm
Sale
13GArcus Biosciences, Inc.
RCUS
Foresite Capital Fund III L.P.2,028,876
4.6%
-2,066,585decrease
(-50.46%)
View
2019-01-23
5:28 pm
Purchase
13GReplimune Group, Inc.
REPL
Foresite Capital Fund III L.P.2,009,312
6.4%
2,009,312increase
(New Position)
View
2018-03-23
2:14 pm
Purchase
13GArcus Biosciences, Inc.
RCUS
Foresite Capital Fund III L.P.4,095,461
9.6%
4,095,461increase
(New Position)
View